Aptevo Therapeutics Files 8-K

TL;DR

APVO filed an 8-K on 12/29/25 for corporate changes & financials.

AI Summary

Aptevo Therapeutics Inc. filed an 8-K on December 29, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Seattle, Washington, operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates corporate updates and the submission of financial documents, which are crucial for investors to assess the company's current status and financial health.

Risk Assessment

Risk Level: low — This is a routine filing for corporate updates and financial statements, not indicating any immediate operational or financial distress.

Key Numbers

• 001-37746 — SEC File Number (Identifies the company's filing with the SEC.)
• 81-1567056 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Aptevo Therapeutics Inc. (company) — Registrant
• December 29, 2025 (date) — Date of earliest event reported
• 2401 4th Avenue Suite 1050 (address) — Principal Executive Offices
• Seattle, Washington (location) — Principal Executive Offices Location
• Delaware (location) — State of Incorporation

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar

Filing Documents

• apvo-20251229.htm (8-K) — 51KB
• apvo-ex3_1.htm (EX-3.1) — 16KB
• 0001193125-25-335497.txt ( ) — 182KB
• apvo-20251229.xsd (EX-101.SCH) — 26KB
• apvo-20251229_htm.xml (XML) — 5KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. (a) Amendment of Articles of Incorporation to Effect Reverse Stock Split On July 24, 2025, Aptevo Therapeutics Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") at which the Company's stockholders approved a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect, at the option of the Board of Directors of the Company (the "Board"), a reverse split of the Company's common stock at a ratio ranging from 1-for-6 to 1-for-22, inclusive, with the effectiveness of one of such amendments and the abandonment of the other amendments, or the abandonment of all amendments, to be determined by the Board in its sole discretion following the Special Meeting. On December 17, 2025, the Board approved an amendment to the Certificate of Incorporation to effect a reverse stock split of its common stock at the reverse split ratio of 1-for-18 (the "Reverse Stock Split"). Accordingly, on December 29, 2025, the Company filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to effect the Reverse Stock Split. The Amendment was effective at 5:01 p.m. Eastern Time on December 29, 2025 (the "Effective Time"). The Amendment provides that, at the Effective Time, every 18 shares of the Company's issued and outstanding common stock was automatically combined into one issued and outstanding share of common stock, without any change in par value per share. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, restricted stock units and warrants, which will result in a proportional decrease in the number of shares of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: December 29, 2025 By: /s/ Marvin L. White President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR